Antagonizing urotensin receptor is a novel therapeutic strategy for glucocorticoid‐induced skeletal muscle atrophy
Main Authors: | Lin Yin, Na Li, Weihua Jia, Nuoqi Wang, Meidai Liang, Jiamin Shang, Guifen Qiang, Guanhua Du, Xiuying Yang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2022-05-01
|
Series: | Clinical and Translational Medicine |
Online Access: | https://doi.org/10.1002/ctm2.879 |
Similar Items
-
Commentary for “antagonizing urotensin receptor is a novel therapeutic strategy for glucocorticoid‐induced skeletal muscle atrophy”
by: Ashok D. Prabakaran, et al.
Published: (2022-06-01) -
Combination of Docking-Based and Pharmacophore-Based Virtual Screening Identifies Novel Agonists That Target the Urotensin Receptor
by: Na Li, et al.
Published: (2022-12-01) -
Kaempferol attenuates nonalcoholic fatty liver disease in type 2 diabetic mice via the Sirt1/AMPK signaling pathway
by: Na Li, et al.
Published: (2023-09-01) -
The Positive Impact of Vitamin D on Glucocorticoid-Dependent Skeletal Muscle Atrophy
by: Mateusz Jakub Karnia, et al.
Published: (2021-03-01) -
Muscle atrophy in response to cytotoxic chemotherapy is dependent on intact glucocorticoid signaling in skeletal muscle.
by: Theodore P Braun, et al.
Published: (2014-01-01)